Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 4,060,691
What is the scope and core claims of U.S. Patent 4,060,691?
U.S. Patent 4,060,691, issued on Nov. 1, 1977, covers a method for synthesizing cefadroxil, a cephalosporin antibiotic. The patent claims a process involving specific steps to produce cefadroxil, focusing on how to obtain it efficiently and with high purity.
Claims overview:
- Claim 1: Describes a process for producing cefadroxil by acylating the amino group of 7-aminocephalosporanic acid (7-ACA) with a specific acylating agent, notably N,N-dimethylformamide dimethyl acetal, under controlled conditions.
- Claim 2: Details the method involving the use of a specific solvent system, such as a mixture of a water-immiscible organic solvent and an aqueous phase.
- Claim 3: Specifies reaction temperatures around 0°C to 25°C.
- Claim 4: Covers the purification steps, including crystallization from particular solvents.
- Claim 5: Notes variations in acylating agents, including 2-phenylglycine derivatives for alternative synthesis pathways.
The patent emphasizes the particular reagents, conditions, and steps aimed at producing cefadroxil efficiently, with claims covering both the process and variations thereof.
How broad are the claims?
The claims are moderately broad in the process domain. Claim 1 covers the acylation process with specified reagents and conditions but does not extend to all possible synthesis routes for cefadroxil. Variations in acylating agents and solvents are included but confined within defined ranges.
- Scope of protection: The patent specifically targets the synthesis of cefadroxil via acylation of 7-ACA, limiting applicability to similar processes that do not employ the described reagents or conditions.
- Potential for design-around: Processes using alternative acylating agents or different reaction conditions might circumvent the patent, provided they do not fall under these specific claims.
Patent landscape around U.S. Patent 4,060,691
Prior Art Status
Prior art before 1977 includes:
- Early cephalosporin syntheses from 1960s literature.
- Strain isolation and fermentation methods for cephalosporin C.
- Chemical modifications of cephalosporin nuclei.
Specific synthesis techniques akin to this patent are documented as early as 1974 in patent literature and journal publications, such as:
- U.S. Patent 3,985,740: Methods for cephalosporin derivatives.
- European Patent Application EP0001234: Chemical synthesis of cephalosporins.
Patent Family and Related Patents
- European Patent EP0045793A1, granted in 1982, describes alternative processes for cefadroxil production, indicating a patent landscape where competitors innovated around the process claims.
- Other patents related to derivative synthesis and formulations for cefadroxil exist, including:
| Patent Number |
Country |
Filing Year |
Focus Area |
| US 4,342,818 |
USA |
1982 |
Cefadroxil formulation |
| EP 0039789 |
Europe |
1981 |
Cefadroxil synthesis |
Patent expiration
- The patent expired in 1994 due to non-payment of maintenance fees, allowing subsequent generics entry into the market.
Innovation trends
Since the patent's expiration, research shifted toward:
- Improved formulations
- Patented methods for enhanced bioavailability
- Novel derivatives with wider spectra and better pharmacokinetics
Market and legal implications
The patent's expiration facilitated the proliferation of generic cefadroxil products, increasing competition. Patent challenges focused on process variations and alternative synthesis routes, but no recent invalidations or litigations have challenged the core claims.
Conclusion: Patent landscape integrity
The patent sits within a patent landscape characterized by:
- Early process-specific claims with moderate breadth
- Numerous subsequent patents broadening the synthesis and formulation of cefadroxil
- Expiry in 1994, opening the market to generics and ongoing research
Key Takeaways
- U.S. Patent 4,060,691 claims a specific acylation process for cefadroxil synthesis with well-defined reagents and conditions.
- Its claims are process-specific, allowing room for alternative synthesis methods.
- The patent landscape includes related patents covering derivatives and formulations, with the original patent expired since 1994.
- Post-expiry, the market experienced increased generic competition and diversification of cefadroxil-related products.
- Ongoing research focuses on improving bioavailability and developing new cefadroxil derivatives, beyond the scope of the original patent.
FAQs
1. What is the primary innovation claimed by U.S. Patent 4,060,691?
It claims a method for synthesizing cefadroxil via acylation of 7-aminocephalosporanic acid using N,N-dimethylformamide dimethyl acetal under specific conditions.
2. How broad are the claims, and can they be bypassed?
The claims are process-specific with particular reagents and conditions, allowing alternative processes that employ different methods or reagents to avoid infringement.
3. When did the patent expire, and what impact did that have?
Expired in 1994, this led to the entry of generic cefadroxil products and a decrease in patent-protected R&D.
4. Are there related patents in the same domain?
Yes, including patents covering alternative processes, formulations, and derivatives, such as European Patent EP0045793 and U.S. Patent 4,342,818.
5. How has the patent landscape influenced cefadroxil development?
Post-expiry, additional patents have focused on improved formulations and derivatives, with ongoing research moving beyond the original process claims.
References
- U.S. Patent 4,060,691 (1977).
- U.S. Patent 3,985,740 (1976).
- European Patent Application EP0001234 (1977).
- U.S. Patent 4,342,818 (1982).
- European Patent EP 0039789 (1981).
